Analysis Group to Present New Outcomes Research at 2024 ASCO Annual Meeting
Event:2024 ASCO Annual Meeting
Dates:
May 31–June 4, 2024
Host:
American Society of Clinical Oncology (ASCO)
Location:
Chicago, IL, and online
Members of Analysis Group’s HEOR, Epidemiology & Market Access practice will present seven posters at the 2024 ASCO Annual Meeting. The program will feature a range of educational and scientific sessions on cancer research, treatment, and patient care.
Analysis Group poster presentations include:
“Real-world monitoring and treatment patterns in von Hippel-Lindau (VHL) disease-associated central nervous system hemangioblastomas (CNS-Hb),” coauthored by an Analysis Group team – including Managing Principal James Signorovitch, Vice President Yan Song, Manager Jonathan Freimark, and Senior Analyst Manasi Mohan – in collaboration with researchers from Merck and The University of Texas MD Anderson Cancer Center. Funding for this study was provided by Merck & Co., Inc.
“Real-world evidence of overall survival (OS) and treatment patterns of patients (pts) with testicular germ cell tumors (GCT) receiving palliative chemotherapy in the United States,” coauthored by an Analysis Group team – including Managing Principal Annie Guérin, Vice President Patrick S. Gagnon, Manager Jessica Maitland, Associate Philippe Boileau, and Senior Research Professional Kana Yokoji – in collaboration with researchers from Memorial Sloan Kettering Cancer Center and BioNTech. Funding for this study was provided by BioNTech.
“Short-term risk of recurrence in patients (pts) with HR+/HER2− early breast cancer (EBC) treated with endocrine therapy (ET) in randomized clinical trials (RCTs): A meta-analysis,” coauthored by an Analysis Group team – including Principal Dave Nellesen, Manager David Proudman, Associate Samantha Kaufhold, and Analysts Adrienne Kwok and Olivia Shane – in collaboration with researchers from the University of Milan and European Institute of Oncology, IRCCS, Instituto de Investigación Sanitaria Hospital 12 de Octubre, Winship Cancer Institute of Emory University, Novartis, University Hospital Erlangen, and Sarah Cannon Research Institute. Funding for this study was provided by Novartis.
“Cost-effectiveness analysis of later-line treatments for refractory metastatic colorectal cancer,” coauthored by an Analysis Group team – including Vice President Min Yang and Associate Sang Cho – in collaboration with researchers from the Mayo Clinic Comprehensive Cancer Center, Bayer, and AccessHope. Funding for this study was provided by Bayer Healthcare Pharmaceuticals.
“Indirect comparison of linvoseltamab versus teclistamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM),” coauthored by an Analysis Group team – including Vice Presidents Jenny Zhou and Viviana García-Horton, Manager Mirko Fillbrunn, and Senior Analysts Hong Wang and Matthew Mattera – in collaboration with researchers from the Icahn School of Medicine at Mount Sinai, The University of Texas MD Anderson Cancer Center, Karmanos Cancer Institute, University of Miami Health System, Regeneron, and The Ohio State University Comprehensive Cancer Center. Funding for this study was provided by Regeneron Pharmaceuticals, Inc.
“Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An updated indirect treatment comparison (ITC),” coauthored by an Analysis Group team – including Vice Presidents Jenny Zhou and Viviana García-Horton and Senior Analyst Dana Christensen – and researchers from the University of Essen, the German Cancer Consortium, The University of Texas MD Anderson Cancer Center, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Dana-Farber Cancer Institute, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, The Royal Marsden Hospital NHS Foundation Trust, the University of Michigan, Aix-Marseille University, Hôpital de la Timone, Bristol Myers Squibb, Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals. Funding for this study was provided by Bristol Myers Squibb.